A Study of Ivonescimab in First-Line ES-SCLC

The goal of this clinical trial is to learn if different combinations of a drug called Ivonescimab, along with chemotherapy and other investigational drugs, are safe and effective for the initial treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). The main questions the study aims to answer are: * What side effects do participants experience from these combination treatments? * How well do the treatments work to shrink tumors? Researchers will compare three groups to see which combination works best. All participants will receive Ivonescimab and chemotherapy (etoposid

Trial Details

NCT ID

NCT07245446

Phase

PHASE2

Sponsor

Akeso

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

Ivonescimab
Cadonilimab
AK117
Etoposide
Carboplatin (AUC 5)

Locations (sample)

Beijing, Beijing Municipality, China|39.9075,116.39723
Xi'an, Shaanxi, China|34.25833,108.92861
Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

Histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC).
No prior systemic therapy for ES-SCLC.
At least one measurable lesion as defined by RECIST v1.1.
Age 18 to 75 years.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →